B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. by Tuscano, Joseph M & Sands, Jacob
UC Davis
UC Davis Previously Published Works
Title
B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis.
Permalink
https://escholarship.org/uc/item/7t32054w
Authors
Tuscano, Joseph M
Sands, Jacob
Publication Date
2009
DOI
10.2147/btt.2009.3126
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
© 2009 Tuscano and Sands, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Biologics: Targets & Therapy 2009:3 225–232
Biologics: Targets & Therapy
225
r e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
B cell reductive therapy with rituximab 
in the treatment of rheumatoid arthritis
Joseph M Tuscano1,2 
Jacob Sands1,2
1Hematology and Oncology, veterans 
Affairs, Northern California 
Health Care System, California, 
USA; 2Division of Hematology 
and Oncology, University of California, 
Davis School of Medicine, Sacramento, 
California, USA
Correspondence:  Joseph M Tuscano 
Department of internal Medicine,  
University of California, Davis Cancer  
Center, Sacramento, CA 95817, USA 
Tel + 1 916 734 3771 
Fax + 1 916 734 7946 
email joseph.tuscano@ucdmc.ucdavis.edu
Abstract: The approach to treating autoimmune disorders is currently undergoing a significant 
change in focus. As therapies are developed that are more precise in targeting the pathogenesis 
for these diseases, patients experience significantly fewer side effects. At the same time, as more 
precise therapies are discovered, the etiologies of these diseases become further elucidated. 
It is now widely accepted that B-lymphocytes play a significant role in the pathogenesis of 
various autoimmune diseases, the extent of which continues to be the focus of ongoing research. 
Rheumatoid arthritis is one such disease process that has been the focus of various B-lymphocyte-
directed therapeutic trials. In this paper we review the current research available on rituximab 
as treatment for rheumatoid arthritis. This review details results from four main studies, as well 
as others, which used rituximab in at least one of the arms in treatment of rheumatoid arthritis. 
The results are promising and will likely lead to longer term studies as well as a potential focus 
on B cell subsets.
Keywords: rheumatoid arthritis, rituximab, treatment efficacy, autoimmune, B-cells
Introduction
Treatment for autoimmune disorders is in the midst of a significant change. Therapies 
with nonspecific immunosuppressive agents are being replaced with therapies that have 
specific targets that have selective effects on a wide range of cell types, cytokines, and 
signaling pathways. Targeted therapies for autoimmune disease will not only provide 
the promise of improved efficacy and decreased toxicity, but will also deliver new 
insights into disease pathogenesis.
Rheumatoid arthritis (RA) is a relatively common disorder, affecting about 1% of 
the population, both in the United States and throughout the world.1 The etiology is 
not completely understood, but some important details have recently been elucidated. 
As the disease becomes better understood, specific targets are being identified opening 
the door to an array of therapeutic options. Rituximab, a chimeric monoclonal antibody 
(mAb) that targets human CD20, was approved by the US Food and Drug Administra-
tion (FDA) in 2006 for the treatment of RA and is the subject of this review.
RA results from the proliferation of synovial tissue, increased production of 
synovial fluid, and eventually destruction of bone and cartilage. Although RA was 
previously believed to be a disease affecting only the joints, it has now been shown 
to have significant systemic affects, with associated morbidity and mortality. The 
role of humoral versus cellular immune activity in the resultant disease process is 
not completely known although recent data suggests both are involved. T-cells are 
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activated by an unknown initiating process resulting in the 
production of interleukin-1 (IL-1) and tumor necrosis factor-
α (TNF-α), which have been shown to have a significant role 
in the inflammatory process. It is believed that after initia-
tion; autoantigens develop, perpetuating the T-cell activity 
and the disease process. Based on this, RA was previously 
thought of as a disease mediated primarily by T-cells. This 
led to a number of clinical trials that utilized mAbs to reduce 
T cell numbers, including T cell subsets. One such trial used 
an anti-CD4 mAb to reduce the numbers of CD4 + T cells. 
However, this and other T cell reductive trials failed to 
produce any significant clinical benefit suggesting that T-cells 
are not the sole pathologic focus of the disease process.2 More 
recently, the role of B-cells has been explored both in vitro 
and in vivo and have been found to play a significant role in 
the pathogenesis of this disease. Based on this data there has 
been increasing interest in the use of B cell reductive therapy, 
with agents like rituximab for the treatment of RA.3
The primary mechanism by which B cells are thought 
to mediate the RA pathologic process is by autoantibody 
production. However B cells are also capable of antigen 
presentation to T cells for expansion of the immune response. 
While the antigen that is presented to activate T-cells in RA 
is not known, B cells are thought to mediate the destructive 
process. B cells also activate macrophages and dendritic 
cells, promoting the inflammatory process that occurs in 
the synovia of patients with RA.4 B cells mature into plasma 
cells, which produce rheumatoid factor (RF), present in 
approximately 80% of patients with RA. RF is an antibody 
that binds to the Fc region of immunoglobulin G (IgG) and 
generally portends a poorer prognosis. Interestingly, RF is 
also sometimes found in people without RA, but this RF is 
IgM and often transient with low affinity for macrophages 
and neutrophils. Conversely, in RA, RF is a high affinity IgG 
with the capability of migration into extravascular spaces.5 
Due to the low specificity of RF, anti-cyclic citrullinated 
peptide antibody (CCP) is also used in diagnosis of rheu-
matoid arthritis given the high specificity of this antibody 
as well as increased sensitivity when using both tests. Anti-
CCP may be especially helpful in early diagnosis of RA.6,7 
In one meta-analysis assessing IgM RF and anti-CCP, the 
sensitivity and specificity of IgM RF was 69% and 85% 
respectively, compared with 67% and 95% for anti-CCP.8 
The authors recommended anti-CCP be used alone in test-
ing patients with low pretest probability for RA to prevent 
excessive false positives. They recommended testing both 
RF and anti-CCP in patients with higher pretest probability 
to increase sensitivity, allowing for early treatment.
As the etiology of autoimmune diseases becomes better 
understood, more targeted therapeutics can be developed. 
These targeted approaches will begin to dissect the immune 
response in vivo and give us a better understanding of the 
pathogenic processes in patients with RA. While recent 
studies utilize rituximab as B cell reductive therapy generate 
impressive responses they also teach us that the B cell likely 
has a role beyond production of autoantibodies, as evidenced 
by the improvement in the clinical picture of patients with 
RA despite stable autoantibody levels.9,10
The role of B cells 
in the pathogenesis of RA
Autoantibodies
The mere presence of autoantibodies is prima facie evidence 
for a role for B cells in autoimmune disease pathogenesis. 
Autoantibody levels are incorporated into diagnostic and 
prognostic criteria for clinical assessment, and serve as 
surrogate markers of disease activity. For example, the 
presence of anti-nuclear antibodies (ANA) serves as a very 
sensitive diagnostic marker for systemic lupus erythematosis 
(SLE).11 However, this serologic marker is observed in a 
variety of other autoimmune disorders, and the autoanti-
body level does not correlate with the severity of disease. 
However, many autoantibody levels poorly correlate with 
disease severity and are not thought to play a role in disease 
pathogenesis. This may only reflect our lack of understanding 
of disease pathogenesis, as there are many other autoanti-
bodies that provide highly specific criteria for diagnosis of 
a clinical syndrome. Besides the rheumatologic disorders, 
examples of pathologic autoantibodies include the anti-
acetylcholine receptor (AChR)12 and the anti-glomerular 
basement membrane (GBM) antibodies in myasthenia gravis 
and Goodpastures syndrome, respectively.12,13 The benefi-
cial effect of suppression and removal of these pathologic 
antibodies with immunosuppressive agents or plasmapheresis 
support a definitive role for B cells in the pathogenesis of 
autoimmune disease.
immune complex formation
Autoantibodies produce pathologic effects through various 
mechanisms including binding to antigens, immune complex 
(IC) formation, tissue deposition, complement and Fc 
receptor activation. Immune complexes are seen in various 
autoimmune diseases and the effects can be diffuse, including 
vasculitis, pulmonary hemorrhage, and renal failure. Essen-
tial mixed cryoglobulinemia is an example of an IC-mediated 
disease. Deposition of immune complexes may result in 
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cutaneous purpuric lesions, mononeuritis multiplex, and 
glomerulonephritis.12 Immunosuppressive drugs, or even 
plasmapheresis, are given to reduce immune complex forma-
tion by decreasing cryoglobulin production.
In some studies, genetic differences in Fc receptors have 
been associated with various autoimmune diseases, such 
as immune thrombocytopenia (ITP), SLE, and multiple 
sclerosis (MS).14,15 It is suspected that the different Fc 
receptors may result in longer IC circulation, resulting in 
deposition in tissue, inflammatory reactions, and proliferative 
responses of FcR-bearing cells. Ultimately tissue destruction 
is observed.
The presence of ICs also results in additional indirect 
effects such as complement activation, production of pro-
inflammatory compounds, increased phagocytosis, and 
enhanced cellular and humoral immune responses, which 
also produce autoimmune disease.16
Antibody-independent B cell dependent 
mechanisms
Although B cells produce antibodies, there are other mecha-
nisms by which they cause autoimmune disease, likely 
through effects on T cell activity. MLR/lpr autoimmune 
prone mice engineered not produce immunoglobulin, but 
with otherwise normal B cell functions still develop intersti-
tial nephritis, vasculitis, and glomerulonephritis. Mortality is 
also similar to the mice made to retain the ability to secrete 
immunoglobulin.17 Moreover JHD MLR/lpr mice made defi-
cient of B cells develop significantly less disease than their 
normal B cell producing counterparts. These results suggest 
B cells are integral to autoimmune disease pathogenesis by 
methods other than immunoglobulin production.18 This has 
been hypothesized to be secondary to increased T cell activa-
tion via antigen presentation by B cells.
Intravenous immunoglobulin (IVIG) is used to treat 
symptoms of ITP, specifically increased platelet destruc-
tion by an autoimmune process involving platelet surface 
glycoproteins.19,20 The possible mechanisms of action of 
IVIG imply complement and Fc receptors (FcR) have a 
role in B cell mediated autoimmunity. IVIG may have its 
effect via inhibition of complement or by blocking the FcR, 
resulting in decreased clearance of platelets coated anti-
body. There is evidence that in a murine model of ITP, the 
presence of the Fc(γ)RIIB receptor has a significant impact 
on effectiveness of IVIG in treating ITP.21 Rituximab has 
also shown a significant response in treating patients with 
ITP who have failed other therapies, including steroids and 
splenectomy.22–25 suggesting a B cell-mediated pathogenesis. 
Response to rituximab in ITP patients is observed as two 
possible time courses, suggesting different mechanisms of 
action. There are some that respond within days, potentially 
through inhibition of FcRs, but others respond over weeks, 
which may be due to B cell depletion. Though IVIG and 
rituximab have shown some efficacy, it is limited, suggesting 
other mechanisms of pathogenesis besides those that are 
B cell-mediated, that remain unknown.
Rituximab
Rituximab is a chimeric human/mouse IgG1 antibody 
directed at human CD20, which is found on only pre-B and 
mature B cells. CD20 is not found on plasma cells, stem cells, 
or pro-B cells, and therefore eliminating the CD20 positive 
population does not prevent recovery of mature B cells 
or immunoglobulin production. Rituximab has been used 
and was initially FDA approved for the treatment of B cell 
lymphoma in 1997. More than 90% of  B-cell non-Hodgkin’s 
lymphoma (NHL) express CD20,26 making a CD20 an ideal 
therapeutic target. Various trials have been completed to 
evaluate the efficacy of rituximab both in combination and 
as a single agent. Many trials have shown rituximab to have 
significant efficacy as therapy for various subtypes of NHL 
and it is now the established standard of care for most sub-
types of B cell NHL.27 Rituximab is very well tolerated with 
grade 1–2 infusion reactions as the most common adverse 
event, but this was typically observed after only the first dose 
and has rarely limited administration.
rituximab for the treatment of rA
As for the treatment of NHL the optimal dose and schedule of 
rituximab for the treatment of RA has not been established. 
However several phase II trials have demonstrated clinical 
efficacy with a range of doses from 375 mg/m2 weekly for 
four weeks, 500 mg given as two doses or a single dose of 
1000 mg. All have been well tolerated with a mean termi-
nal half-life of 19–22 days after the second infusion but a 
systemic clearance time of about 240 days and a volume of 
distribution of about 3.6–4.5 L. The pharmacokinetics of 
rituximab has been shown to be unchanged when used in 
combination with cyclophosphamide (CTX) or methotrexate 
(MTX), both of which have demonstrated efficacy when 
used in combination with rituximab in patients with RA.29,30 
Rituximab has been shown to be well tolerated without 
significant side effects29 in patients with RA. There have 
been some pharmacokinetic differences between the dosing 
for non-Hodgkin’s lymphoma and RA, although the clinical 
implications of this difference are not known. Though it is 
Biologics: Targets & Therapy 2009:3228
Tuscano and Sands Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
dosed by body surface area for non-Hodgkin’s lymphoma, 
standardized rituximab dosing for rheumatoid arthritis 
works well for a broad range of body surface areas.30 This 
is possibly due to the enormous variation in target density 
in patients with NHL.
There have been several randomized clinical trials that 
have demonstrated clinical efficacy in RA patients that have 
failed standard treatment approaches (Table 1). The DANCER 
trial is a randomized, placebo-controlled trial that examined 
two different doses of rituximab in patients with active 
moderate to severe RA that have failed previous treatments 
with disease-modifying antirheumatic drugs (DMARDs) 
(beyond MTX) as well as biologic response modifiers.31 
Patients in this study were either previously treated with 
MTX or were being treated throughout the study, however 
they were not taking any other DMARD or other biologic 
therapy during the study period. Patients were randomized to 
three different treatment arms; (all containing MTX), placebo 
(MTX alone) versus rituximab 500 mg × 2, versus rituximab 
1000 mg ×  2. At the end of the study (24-weeks), the response 
rate was significantly better in each of the rituximab groups 
when compared to MTX alone. The 500 mg and 1000 mg 
doses show little differences in the ACR20 and 50 groups, 
but of those achieving an ACR70 response, the 1000 mg 
group had a more significant response.
In patients that received steroid treatment or pre-treatment 
there was no statistical difference in efficacy, suggesting 
methylprednisolone and prednisone do not affect treatment 
outcomes in patients receiving rituximab. However, there 
was a difference in infusion-related side effects suggesting 
that premedication with steroids can reduce the incidence 
and severity of rituximab-mediated infusion reactions (which 
were noted more frequently with the first infusion).
In addition to clinical endpoints, biologic measures also 
improved in the rituximab treatment arms, which included a 
significant decrease in C-reactive protein (CRP) levels and 
RF titers. The vast majority of reported adverse events in 
the treatment groups were mild to moderate in severity and 
were similar in all treatment groups with the exception of 
infusion-related toxicity, which was higher in the treatment 
arms that included rituximab.
The DANCER study demonstrated significant clinical 
benefit when rituximab was used in combination with MTX 
in RF-positive patients who have failed previous treatment 
with DMARDs. In this study there was no significant differ-
ence between the 500 mg and 1000 mg rituximab treatment 
groups. The study results also suggest a benefit for the use 
of methylprednisolone pre-medication for the prevention of 
infusion-related toxicity. Other toxicities were modest and 
balanced among the treatment groups. In terms of immu-
nosupression there was no significant change in overall 
immunoglobulin levels and anti-tetanus titers.
In addition, a recent report of  the same study assessed health-
related quality of life which revealed statistically significant 
improvements in the 500 mg and 1000 mg rituximab-treated 
groups compared to MTX alone for physical function, pain, 
Table 1 The proportion of patients with American College of rheumatology criteria scores (ACr) at 24 weeks. rituximab dosing 
was 1000 mg with the noted exception
Primary author Treatment Patients (n) ACR20 % (p) ACR50 % (p) ACR70 % (p) Serious adverse 
event (%)
emery (DANCer) MTX + placebo rituximab 149 28 13 5 18
rituximab 500 mg + MTX 124 55 (0.001) 33 (0.001) 13 (0.029) 17
rituximab + MTX 192 54 (0.001) 34 (0.001) 20 (0.001) 17
Cohen (reFLeX) MTX + placebo rituximab 201 18 5 1 20
rituximab + MTX 298 51 (0.0001) 27 (0.0001) 12 (0.0001) 18
Strand MTX + placebo rituximab 40 15 5 2
rituximab 40 26 (0.05) 13 6
rituximab + MTX 40 29 (0.01) 17 (0.01) 9 (0.05)
rituximab + CTX 41 31 (0.01) 17 (0.01) 6
edwards MTX + placebo Rituximab + CTX 40 38 13 5 8
rituximab + placebo MTX & CTX 40 65 (0.025) 33 (0.059) 15 5
rituximab + MTX + placebo CTX 40 73 (0.003) 43 (0.005) 23 (0.048) 8
rituximab + CTX + placebo MTX 41 76 (0.001) 41 (0.005) 15 15
Abbreviations: CTX, cyclophosphamide; MTX, methotrexate.
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vitality, social function, and role-physical subscale scores.32 
This study also demonstrated a significant improvement in 
Health Assessment Questionnaire results with the 1000 mg 
rituximab group compared to MTX alone by week 8. The 
500 mg rituximab group first demonstrated significant 
improvement at week 12 and these were maintained over the 
24 weeks of the assessment period. Both rituximab groups 
also demonstrated significant improvements in fatigue 
scores at 12 week, which persisted to the end of the study. 
However there was no significant difference in the mental 
component summary. The authors point out that effects are 
likely seen in pain, mobility, physical function and physical 
role activity scales before being seen in emotional well-being 
scales, which has been observed in other studies that utilize 
biologics including; etanercept,33,34 adalimumab,35,36 and 
infliximab.34,37
Another large randomized trial included participants that 
have been heavily pretreated with multiple agents including 
DMARDs and biologics, (REFLEX trial;38 Table 1). The 
participants in this trial had active rheumatoid arthritis despite 
prior therapy with MTX and anti-TNF agents including 
infliximab, adalimumab, or etanercept. Patients were random-
ized to either placebo or rituximab. Both groups continued 
to take MTX and methylprednisolone prior to and after 
enrolment. Though this study was designed for two-year 
follow-up, the initial publication reported an assessment 
24 weeks after treatment initiation. At 24 weeks there was a 
significant improvement in the rituximab group compared to 
placebo with 51% and 18% achieving an ACR20 response 
respectively. Similar to what was observed in the DANCER 
trial, significant initial responses were observed as early 
as 8 weeks after treatment initiation.32 The ACR50 and 
70 responses were also significantly improved in the ritux-
imab group relative to placebo starting at weeks 12 and 16. 
CRP and erythrocyte sedimentation rate (ESR) levels were 
improved in the rituximab treatment arms as well. Radio-
graphic changes were compared and demonstrated a trend 
toward less progression of joint damage in rituximab-treated 
patients. Significant reduction of joint narrowing scores 
was observed in the rituximab treated patients compared to 
placebo as measured by the Genant-modified Sharp assess-
ment. CD19 + cells were assessed to evaluate peripheral 
B cell levels which revealed a rapid and significant decrease 
after rituximab dosing, with some recovery of B cell counts 
beginning between weeks 16 and 20, however mean immu-
noglobulin levels showed no significant change. The adverse 
events reported were similar between groups, and like the 
DANCER trial, many were mild or moderate. There was no 
significant difference in the incidence of infections between 
the two groups.
In summary, similar to the results of the DANCER 
trial, significant improvements were noted in many of the 
measured outcomes in those patients receiving rituximab 
and MTX when compared with MTX alone. The REFLEX 
trial demonstrated that heavily pretreated patients treated 
with rituximab had significant improvements in nearly 
all areas that were assessed including: swollen and tender 
joint counts, patient’s and physician’s global assessments 
of disease activity, pain scores, HAQ DI scores, CRP and 
ESR levels, mental and physical health scores (measured by 
SF-36), fatigue scores, and a trend toward improvement in 
joint narrowing assessed radiogaphically.
Two additional smaller, placebo-controlled, double-blind 
studies that assessed the use of rituximab for the treatment 
of RA also deserve mention. These studies also included 
treatment groups that received rituximab alone, MTX alone 
as well as rituximab plus CTX.10,39 ACR20, 50, and 70 scores 
improved in the rituximab treatment groups when compared 
to MTX alone (Table 1). Edwards and colleagues continued 
to follow the various treatment arms to week 48.10 ACR20 
and 50 criteria continued to demonstrate significant improve-
ments in the patients treated with rituximab and MTX, as well 
as patients treated with rituximab and CTX. Edwards and 
colleagues also measured CD-19 + B cell levels and similar 
to the previously mentioned studies, they also demonstrated 
a significant reduction post-rituximab treatment without 
significant change in immunoglobulin levels. RF levels 
decreased initially in all treatment arms, but the rituximab 
treatment arms were more likely to be sustained at week 12 
and continued to be lower at week 24 compared to MTX 
alone. Like the DANCER and REFLEX trials, the incidence 
of infection was not significantly different between the 
different treatment arms. The incidence of adverse events was 
similar in all treatment groups. Additionally, 85%–90% of 
adverse events that occurred with rituximab infusions were 
mild to moderate in severity and again were more likely after 
the first infusion.
In a study conducted by Strand and colleagues, the 
treatment groups were followed for two years.39 At 104 weeks, 
patients treated with rituximab and MTX demonstrated 
persistent clinical improvement when compared to other 
treatment groups. Although the rituximab and MTX group 
showed higher numbers of patients achieving ACR20, 
50, and 70 scores when compared to all other treatment 
groups at 104 weeks, this was not statistically significant. 
However assessments via Health Assessment Questionnaire 
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measurements demonstrated significant improvements at 
week 72 compared to baseline in all treatment groups including 
MTX alone, although the magnitude of the improvement was 
greater in the treatment groups that included rituximab.
More recently, analysis of the synovia of patients with RA 
receiving rituximab has demonstrated reduction of B cells and 
inhibition of structural joint damage.40–43 Persistence of RA 
symptoms despite treatment with rituximab has been shown 
to correlate with persistence of both plasma cells as well as 
synovial B cells.41 Thurlings and colleagues hypothesize that 
rituximab has “an indirect effect on short-lived autoreac-
tive plasma cells that are associated with the production of 
autoantibodies”.
As the efficacy of rituximab has become more established, 
there are studies directed at understanding which patients 
will best respond to rituximab treatment for RA. Antibody 
analysis of synovia has shown clinical improvement related 
to reduction of IgG, IgM, and Igκ.42 Interestingly, reduction 
of interleukin-8 was observed in clinical nonresponders. 
Peripheral IgD + CD27 + memory B cell levels at the time 
of B cell recovery have also been shown to be significantly 
higher in nonresponders as well as early relapse.44 Initial 
studies had shown no significant difference in peripheral 
B cell numbers between responders to rituximab and 
nonresponders. Dass and colleagues performed an analysis 
of patients receiving rituximab using a highly sensitive tech-
nique for detecting B cells.45 Utilizing MRD flow cytometry 
techniques, B cells were measured at lower numbers than 
conventional analysis is able to detect. The results demon-
strated a statistically significant decrease in peripheral B cell 
numbers amongst responders relative to nonresponders. 
Those who had undetectable peripheral B cell levels after 
the first infusion were more likely to have a better clinical 
response as well. Interestingly, those who had a complete 
B cell depletion after the second infusion, still were less 
likely to show significant clinical improvement relative to 
those with depletion after the first infusion, making the rate 
of peripheral B cell depletion a seemingly important reason 
for, or surrogate to, clinical improvement.
This observation is further supported by a small study 
conducted by Thurlings and colleagues, which analyzed the 
effects of rituximab after three doses.46 Patients that did not 
respond after the first dose showed no significant reduction 
in symptoms after future doses, suggesting a predictable 
response to effectiveness of rituximab after the first dose. 
Repeat dose timing was based upon symptom relapse. These 
results further strengthen the understanding that rituximab 
has effectiveness because reduction of the number of B cells 
results in decreased autoantibody production and therefore 
less structural joint damage, which then creates improved 
clinical symptoms. Inhibiting this process clearly has effi-
cacy. It continues to remain unknown if those that do not 
respond are affected by another process or if they would 
respond to higher doses.
Conclusion
Rheumatoid arthritis is a destructive and debilitating disease 
that affects millions of adults and children around the world. 
While there are common and typical clinical features, there 
is significant heterogeneity in the details and severity of 
the clinical phenotype. This heterogeneity likely reflects 
considerable variation in the pathogenesis and reaction to 
the autoimmune process in a given patient. Nonspecific 
anti-inflammatory agents have provided considerable relief 
for patients for many years, although typically limited and 
often at the cost of considerable toxicity. Newer targeted 
approaches to this disease are providing more effective 
and less toxic treatment approaches. More importantly, 
as we further dissect the immune response and develop 
more specifically targeted agents, these provide not only 
the potential for improved clinical outcome but also tools 
for discovery that will allow for a better understanding of 
the pathogenesis of this disease. Clearly there are multiple 
components of the immune system that are involved in 
the pathogenesis of RA, but the studies described herein 
confirm that B cells play an important role, and therapeutics 
that specifically provide B cell reduction have become an 
accepted weapon in the arsenal against this dreadful disease. 
It is important to note that the studies done thus far had 
a short follow-up when considering a potential lifetime 
therapy with rituximab. The side effect profile, as well as 
efficacy, may change when treating for many years. Future 
studies will focus on the long-term effects of B cell reduc-
tive therapy, ideal schedule for rituximab dosing, and the 
efficacy of targeting specific B cell subsets.
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